Welcome to AnaViRx Inc.
AnaViRx is focused exclusively on development of novel small molecule therapeutics against viral infections.
The company has in-licensed worldwide rights to a series of small molecules with unique molecular features that have shown broad antiviral activity.
We have identified and characterized a lead compound (AVX11001) that has a unique pharmacophore and has shown potent inhibitory activity against influenza and we are developing related structures against other virus families including the Flaviviruses (Dengue and West Nile) as well as Filoviruses (Ebola and Marburg).
The influenza therapeutics under development have shown broad strain specificity - with demonstrated activity against H1N1 (swine flu), H3N2 (seasonal flu), H5N1 (avian flu) and others (e.g. H9N2 and even type B Influenza).
The compounds under development have been demonstrated to be potent inhibitors of the viruses both in vitro as well as in vivo. They are easily manufactured, are orally bioavailable and exhibit excellent safety profiles.